公开(公告)号：US08227579B2

公开(公告)日：2012-07-24

申请号：US12870199

申请日：2010-08-27

Applicant: Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

Inventor： Katherine E. Lewis ,  Scott R. Presnell ,  James W. West ,  Robert Mabry ,  Brent Meengs ,  Steven D. Levin

IPC: C12P21/08

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract translation: 本发明涉及通过其p19亚基或IL-17和IL-23（通过p19）阻断，抑制，降低，拮抗或中和IL-17，IL-23的活性。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。

公开(公告)号：US07910540B2

公开(公告)日：2011-03-22

申请号：US11150533

申请日：2005-06-10

Applicant: Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

Inventor： Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

IPC: A61K38/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。

公开(公告)号：US20100316646A1

公开(公告)日：2010-12-16

申请号：US12828575

申请日：2010-07-01

Applicant: ZEREN GAO ,  STEVEN D. LEVIN ,  JANINE BILSBOROUGH ,  JAMES W. WEST ,  CAMERON S. BRANDT ,  ERIC M. CHADWICK

Inventor： ZEREN GAO ,  STEVEN D. LEVIN ,  JANINE BILSBOROUGH ,  JAMES W. WEST ,  CAMERON S. BRANDT ,  ERIC M. CHADWICK

IPC: A61K39/395 ,  C07K16/28 ,  A61P37/02

CPC classification number: C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Abstract translation: 本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子并在T细胞上表达。 本发明还提供了zB7R1与CD155结合的能力的发现。 还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。

公开(公告)号：US07790676B2

公开(公告)日：2010-09-07

申请号：US12055597

申请日：2008-03-26

Applicant: Steven D. Levin ,  Mark W. Rixon ,  Gao Zeren

Inventor： Steven D. Levin ,  Mark W. Rixon ,  Gao Zeren

IPC: A61K38/00 ,  C12N15/09

CPC classification number: C07K14/7155 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Abstract translation: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

公开(公告)号：US06955895B2

公开(公告)日：2005-10-18

申请号：US09895593

申请日：2001-06-28

Applicant: Akhilesh Pandey ,  Katsutoshi Ozaki ,  Heinz Baumann ,  Steven D. Levin ,  Andrew G. Farr ,  Warren J. Leonard ,  Harvey F. Lodish

Inventor： Akhilesh Pandey ,  Katsutoshi Ozaki ,  Heinz Baumann ,  Steven D. Levin ,  Andrew G. Farr ,  Warren J. Leonard ,  Harvey F. Lodish

IPC: A61K38/00 ,  C07K14/715 ,  C12N15/12 ,  C07K14/47 ,  C07K14/705 ,  C12N5/10 ,  C12P21/02

CPC classification number: C07K14/7155 ,  A61K38/00 ,  C07K2319/30

Abstract: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.

公开(公告)号：US08822642B2

公开(公告)日：2014-09-02

申请号：US13701234

申请日：2011-06-07

Applicant: Steven D. Levin ,  Margaret D. Moore ,  Craig D. Ostrander ,  Katherine E. Lewis ,  David W. Taft ,  Robert J. Rosler ,  Anitra Wolf ,  Megan M. Lantry

Inventor： Steven D. Levin ,  Margaret D. Moore ,  Craig D. Ostrander ,  Katherine E. Lewis ,  David W. Taft ,  Robert J. Rosler ,  Anitra Wolf ,  Megan M. Lantry

IPC: C07K14/00 ,  C12N5/10 ,  C07H21/04 ,  A61K38/16

CPC classification number: C07K19/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K2319/30 ,  C07K2319/735 ,  C07K2319/74

Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.

Abstract translation: 公开了与可溶性二聚蛋白有关的组合物和方法。 二聚体蛋白包含通过二聚结构域连接的第一和第二多肽融合物，每个多肽融合物包含对应于细胞表面受体的细胞因子或细胞外结构域的第一和第二单体结构域。 单体域可以位于二聚结构域的氨基末端和羧基末端。 或者，单体域可以与二聚化结构域的羧基末端或氨基末端串联。 二聚体蛋白可用于治疗，诊断和研究的方法。

公开(公告)号：US08268773B2

公开(公告)日：2012-09-18

申请号：US13015304

申请日：2011-01-27

Applicant: Scott R. Presnell ,  Steven K. Burkhead ,  Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

Inventor： Scott R. Presnell ,  Steven K. Burkhead ,  Steven D. Levin ,  Rolf E. Kuestner ,  Zeren Gao ,  Stephen R. Jaspers ,  Janine Bilsborough

IPC: A61K38/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。

公开(公告)号：US20120219540A1

公开(公告)日：2012-08-30

申请号：US13417587

申请日：2012-03-12

Applicant: Zeren Gao ,  Steven D. Levin ,  Janine Bilsborough ,  James W. West ,  Cameron S. Brandt ,  Eric M. Chadwick

Inventor： Zeren Gao ,  Steven D. Levin ,  Janine Bilsborough ,  James W. West ,  Cameron S. Brandt ,  Eric M. Chadwick

IPC: A61K38/17 ,  G01N33/566 ,  A61K31/7105 ,  A61P37/00 ,  A61K39/395 ,  A61K31/713

CPC classification number: C07K16/2827 ,  A61K38/00 ,  A61K2039/507 ,  C07K14/47 ,  C07K14/70532 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12Q1/66 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/70532

Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Abstract translation: 本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。 本发明还提供了zB7R1与CD155结合的能力的发现。 还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。

公开(公告)号：US20120082668A1

公开(公告)日：2012-04-05

申请号：US13293384

申请日：2011-11-10

Applicant: Steven D. LEVIN ,  Mark W. RIXON ,  Gao Zeren

Inventor： Steven D. LEVIN ,  Mark W. RIXON ,  Gao Zeren

IPC: A61K39/395 ,  A61P17/06 ,  A61P19/02 ,  A61P13/12 ,  A61P11/00 ,  A61P11/06 ,  A61P19/10 ,  A61P1/04 ,  A61P1/00 ,  A61P29/00 ,  A61K38/16 ,  A61P9/10

CPC classification number: C07K14/7155 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Abstract translation: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

公开(公告)号：US08093355B2

公开(公告)日：2012-01-10

申请号：US12580112

申请日：2009-10-15

Applicant: Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

Inventor： Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

IPC: C07K1/00 ,  C07K14/00 ,  C07K17/00

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K2121/00 ,  C07K14/715 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括使用可溶性IL-17RC受体IL-17RCx4来治疗炎症的方法。